TSX Venture Exchange Stock Maintenance Bulletins

TSX VENTURE COMPANIES

FLUROTECH LTD. ("TEST.H")
  [formerly FluroTech Ltd. ("TEST")]
  BULLETIN TYPE: Transfer and New Addition to NEX, Symbol Change, Resume Trading
  BULLETIN DATE: October 26, 2023
  TSX Venture Tier 2 Company

Effective at the opening, Monday, October 30, 2023 , the securities of FluroTech Ltd., (the "Company") will resume trading.  Further to the Exchange Bulletin dated April 17, 2023 , a news release was issued on October 6, 2023 , announcing that the Company will not be proceeding with its proposed transaction.  The transaction contemplated would have constituted a Reverse Takeover as defined under Exchange Policy 5.2.

In accordance with TSX Venture Policy 2.5, the Company has not maintained the requirements for a TSX Venture Tier 2 company.  Therefore, effective at the opening on Monday, October 30, 2023 , the Company's listing will transfer to NEX, the Company's Tier classification will change from Tier 2 to NEX, and the Filing and Service Office will change from Calgary to NEX.

As of October 30, 2023 the Company is subject to restrictions on share issuances and certain types of payments as set out in the NEX policies.

The trading symbol for the Company will change from TEST to TEST.H.  There is no change in the Company's name, no change in its CUSIP number and no consolidation of capital.  The symbol extension differentiates NEX symbols from Tier 1 or Tier 2 symbols within the TSX Venture market.

________________________________________

Right Season Investments Corp. ("LITT")
  BULLETIN TYPE:  Consolidation
  BULLETIN DATE: October 26, 2023
  TSX Venture Tier 2   Company

Pursuant to a resolution passed by the shareholders of the Company on October 20, 2023 , the Company has consolidated its capital on a seventy (70) old for one (1)  new basis.  The name of the Company has not been changed.

Effective at the opening October 30, 2023 , the shares of Right Season Investments Corp. will commence trading on TSX Venture Exchange on a consolidated basis. The Company is classified as a 'Financial Services - Investment Companies and Funds' company.

Post - Consolidation

Capitalization:                          Unlimited   shares with no par value of which

2,262,956   shares are issued and outstanding

Escrow                                     Nil   shares are subject to escrow

Transfer Agent:                        Endeavor Trust Corporation

Trading Symbol:                       LITT                  ( UNCHANGED )

CUSIP Number:                       76658Q206 (NEW)

________________________________________

STALLION URANIUM CORP. ("STUD   ")
  [formerly STALLION DISCOVERIES CORP. ("STUD   ")]
  BULLETIN TYPE:  Name Change
  BULLETIN DATE: October 26, 2023
  TSX Venture Tier 2   Company

Pursuant to a resolution passed by directors on October 11, 2023 , the Company has changed its name as follows.  There is no consolidation of capital.

Effective at the opening October 30, 2023 , the common shares of  Stallion Uranium Corp. will commence trading on TSX Venture Exchange, and the common shares of Stallion Discoveries Corp. will be delisted.  The Company is classified as a 'Mining' company.

Capitalization:                                     Unlimited  shares with no par value of which

109,381,286  shares are issued and outstanding

Escrow:                                               nil  common shares

Transfer Agent:                                   Endeavor Trust Corporation

Trading Symbol:                                  STUD                   ( UNCHANGED )

CUSIP Number:                                  852919109            ( NEW )

________________________________________

Sucro Limited   ("SUG")
  B   ULLETIN TYPE: New Listing-Shares
  BULLETIN DATE: October 26, 2023
  TSX Venture Tier 2 Company

The Prospectus of Sucro Limited ("Sucro") dated October 19, 2023 (the "Prospectus") has been filed with and accepted by the Ontario , Alberta , British Columbia Manitoba, New Brunswick , Newfoundland and Labrador , Nova Scotia , Prince Edward Island and Saskatchewan Securities Commissions, effective October 23, 2023 , pursuant to the provisions of the Ontario , Alberta , British Columbia Manitoba, New Brunswick , Newfoundland and Labrador , Nova Scotia , Prince Edward Island and Saskatchewan Securities Acts.

The subordinate voting shares (the "SVS") of the Company will be listed and admitted to trading on TSX Venture Exchange, on the effective dates stated below. Each Proportionate Voting Shares ("PVS") is convertible into one hundred (100) SVS. Only the SVS will be listed on the Exchange.

The gross proceeds to be received by the Company for the Offering Are C$15,004,000 , being 1,364,000 SVS at C$11 per SVS, plus up to an additional 15% if over-allotment option is exercised in full.

Listing Date:                  At the close of business ( 5:01 p.m. EDT ) on Friday, October 27, 2023 .

Commence Date:          The SVS will commence trading on TSX Venture Exchange at the opening on Monday, October 30, 2023 , upon confirmation of closing.

The closing of the public offering is scheduled to occur before the market opening on Monday, October 30, 2023 . A further notice will be issued upon receipt of closing confirmation.

For further information, please refer to the Company's Prospectus dated October 19, 2023 available on SEDAR+ and to the Company's news releases dated October 23, 2023 .

Corporate Jurisdiction: Cayman Islands

Capitalization:

Authorized:       490,000,000 SVS and 1,000,000 PVS

with a par value of US$0.0001 per SVS and US$0.001 per PVS, of which

Issued and Outstanding: 6,528,421 SVS and 167,189 PVS (not listed)

Escrowed Securities:     1,153,244 SVS and 167,189 PVS of which

115,324 SVS and 16,718 PVS are released as at the date of this bulletin

Transfer Agent:             Odyssey Trust Company

Trading Symbol: SUG

CUSIP Number: G8544S107

The Company is classified as a "Sugar Manufacturing" company (NAICS: 311310).

Company Contact:                    Stefano D'Aniello, CFO

Company Address:                   2020 Ponce de Leon Blvd., Suite 1204 Coral Gables, Florida 33134 USA Company Phone Number:             (305) 901-1322

Company Email Address: sdaniello@sucro.us

Company Website: www.sucro.us

________________________________________

THE WELL TOLD COMPANY INC.   ("WLCO.H")
 

LITT:CC
The Conversation (0)
The Radoff-JEC Group Nominates Three Highly Qualified Candidates for Election to the Atea Pharmaceuticals Board of Directors

The Radoff-JEC Group Nominates Three Highly Qualified Candidates for Election to the Atea Pharmaceuticals Board of Directors

Issues Open Letter to Atea's Stockholders Outlining the Case for Boardroom Change Based on Years of Stock Price Underperformance, Poor Decision-Making and Entrenchment Maneuvers

Believes its Three Highly Qualified Director Candidates Possess the Necessary Ownership Perspectives, Scientific Credibility and Public Company Board Experience to Create Value for Stockholders

News Provided by Business Wire via QuoteMedia

Keep reading...Show less
The Radoff-JEC Group Nominates Three Highly Qualified Candidates for Election to the Atea Pharmaceuticals Board of Directors

The Radoff-JEC Group Nominates Three Highly Qualified Candidates for Election to the Atea Pharmaceuticals Board of Directors

Issues Open Letter to Atea's Stockholders Outlining the Case for Boardroom Change Based on Years of Stock Price Underperformance, Poor Decision-Making and Entrenchment Maneuvers

Believes its Three Highly Qualified Director Candidates Possess the Necessary Ownership Perspectives, Scientific Credibility and Public Company Board Experience to Create Value for Stockholders

News Provided by Business Wire via QuoteMedia

Keep reading...Show less
Allergan Aesthetics Emphasizes Commitment to Innovation, Science and a Patient Centric Approach at AMWC 2025

Allergan Aesthetics Emphasizes Commitment to Innovation, Science and a Patient Centric Approach at AMWC 2025

  • Four expert-led educational events with Allergan Medical Institute (AMI), Science of Aging TM and Allergan Aesthetics (AA) Global Medical Affairs
  • AMI symposia will focus on a new Allergan Aesthetics (AA) Signature Program and celebrate 10 years of MD Codes™, with live injection sessions and fireside chat with world-renowned plastic surgeon Dr. Maurício de Maio
  • Eleven E-Poster data presentations and Meet the Expert sessions with Global experts live from the Allergan Aesthetics booth

Allergan Aesthetics, an AbbVie company, the industry leader in aesthetics globally, demonstrates how to elevate the patient experience and achieve optimal treatment outcomes with new AA Signature program at the Anti-Aging and Aesthetics Medicine World Congress (AMWC) in Monaco from Thursday, March 27Saturday, March 29, 2025 .

Activities will center around the new AA Signature program - an innovative approach to treatment planning harnessing the power of Allergan Aesthetics advanced portfolio to address different patient needs, including Lift, Definition and Skin Quality , and a celebration of 10 years of MD Codes™, which has revolutionized aesthetic medicine with innovative methodology to guide injectors' technique and elevate patient outcomes.

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less
Bcal Diagnostics Limited

BCAL Diagnostics Launches BREASTEST plus - Generating First Revenues

BCAL Diagnostics Limited (ASX: BDX) (“BCAL” or “the Company”), an Australian and US-based biotechnology company pioneering non-invasive breast cancer diagnostics, is pleased to announce the commercial launch of BREASTEST plus. This first-in-class blood test is available from Thursday, 27 March 2025 and will be used alongside standard-of-care imaging in breast cancer screening and diagnostics. The Company is pleased that this launch has been achieved within the previously announced target timeframe of having the test commercially available in Australia by the end of 1Q CY2025.

Keep reading...Show less
ELAHERE®  Shows Consistent Survival Benefit in Long-Term Analysis for Certain Ovarian Cancer Patients

ELAHERE® Shows Consistent Survival Benefit in Long-Term Analysis for Certain Ovarian Cancer Patients

  • Final data analysis from Phase 3 MIRASOL trial after 30.5-month median follow-up demonstrated 32% reduction in risk of death with ELAHERE compared to chemotherapy in folate receptor alpha (FRα)-positive platinum-resistant ovarian cancer (PROC)
  • Data presented in a late-breaking oral presentation at the Society of Gynecologic Oncology (SGO) Annual Meeting on Women's Cancer in Seattle

AbbVie (NYSE: ABBV) today announced the final analysis of the confirmatory Phase 3 MIRASOL trial evaluating the efficacy and safety of ELAHERE ® (mirvetuximab soravtansine-gynx) in women with folate receptor alpha (FRα)-positive platinum-resistant ovarian cancer (PROC) compared to chemotherapy. At 30.5 months median follow-up, treatment with ELAHERE continued to show significant improvements in progression-free survival (PFS) and overall survival (OS) compared to investigator's choice (IC) chemotherapy. 1 Ovarian cancer patients often present with late-stage disease and are historically first treated with platinum-based chemotherapy, which they may become resistant to and require another therapy, such as ELAHERE. 2

"Ovarian cancer can be devastating, and when cancer cells stop responding to chemotherapy patients may feel hopeless about their journey. The data presented today reinforce the importance of ELAHERE as a transformative therapy for patients with limited options," said Svetlana Kobina , MD, PhD, vice president, oncology medical affairs, AbbVie. "We remain steadfast in our commitment to bring forward innovative therapies that improve the lives of patients with difficult-to-treat cancers."

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less

Adicet Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Company Progress

Phase 1 clinical trial of ADI-001 in autoimmune diseases ongoing; on track to report preliminary clinical data from lupus nephritis (LN) patient cohort in 1H25

Additional LN clinical data and preliminary clinical data from other autoimmune patient cohorts anticipated in 2H25

News Provided by Business Wire via QuoteMedia

Keep reading...Show less

Latest Press Releases

Related News

×